aoxibuvir

Aoxibuvir (also known as alfosbuvir or SH229) is an orally bioavailable small molecule nucleotide prodrug developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus (HCV) infection. It acts as an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, an essential enzyme for viral replication. Upon entering the cell, aoxibuvir is metabolized into its pharmacologically active triphosphate form (SH229M3), which competes with natural nucleotides for incorporation into the nascent viral RNA strand by the NS5B polymerase, leading to premature chain termination. It has been approved in China (under the brand name Shengnuodi) for use in combination with other direct-acting antivirals (DAAs), such as daclatasvir, for the treatment of pan-genotypic HCV infection across genotypes 1, 2, 3, and 6.

Brand names

Shengnuodi

Other names

alfosbuvir奥曦布韦